Delay discounting: effects of drug dependence and withdrawal
Delay discounting: effects of drug dependence and withdrawal
批准号:
8494025
负责人:
CHARLES P FRANCE
金额:
$26.1万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-15 至 2015-06-30
关键词:
AcuteAdultAffectAgonistAnimalsBehaviorBehavioralBenzodiazepinesChronicDataDevelopmentDiazepamDimensionsDoseDrug AddictionDrug abuseDrug usageFlunitrazepamGrantHeroinHumanImpulsive BehaviorImpulsivityIndividualJuiceKetamineLaboratoriesMacaca mulattaMeasuresMental disordersMonkeysMorphineN-MethylaspartateOpioidOpioid ReceptorOxymorphonePharmaceutical PreparationsPhencyclidinePhysical DependenceProceduresRelapseRiskSelf AdministrationSubstance abuse problemTestingTimeWithdrawaldiscountingdrug abuserdrug of abusedrug withdrawalhigh risk behaviorhuman dataindexingmalenon-drugopioid withdrawalprescription opioidpublic health relevancereinforcerremifentanilresponsetrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Impulsivity, an increased tendency to act without thought or deliberation, is common in psychiatric disorders and often is observed in drug abusers. Although impulsivity might be a predisposing trait that contributes to the development of substance abuse, it might also be a result of drug use, thereby promoting ongoing abuse and possibly relapse. Studies have examined how acute administration of drugs affects impulsivity; however, most drug abuse involves repeated drug administration and often the development of physical dependence, yet few studies have examined how impulsivity is affected by chronic drug administration and its discontinuation. Impulsivity is multidimensional and several procedures have been developed for studying different but equally important dimensions of impulsivity; in one procedure, delay discounting, subjects choose between a smaller reinforcer that is delivered without delay and a larger reinforcer that is delivered after a delay. Increased responding for the smaller, immediately available reinforcer is thought to reflect greater impulsivity. Studies in this application examine effects of acute and chronic opioid treatment, and its discontinuation, on delay discounting in animals because in humans delay discounting is sensitive to opioid treatment and its discontinuation. Data from humans suggest that impulsivity contributes to drug abuse and that drug abuse increases impulsivity; delay discounting might also vary across different reinforcers (e.g., money versus drug). Proposed studies build on preliminary data showing that delay discounting is affected by daily administration of very small doses of morphine, suggesting that abuse of even small doses of drugs (e.g., prescription opioids) could significantly increase impulsivity. These studies examine how acute and chronic treatment with a prototypic 5 opioid receptor agonist (morphine), as well as discontinuation of treatment, impact delay discounting in adult male rhesus monkeys. Studies under AIM 1 build on preliminary studies and compare acute drug effects on delay discounting in monkeys responding for a non-drug reinforcer to effects in monkeys responding for a drug reinforcer; these studies test whether delay discounting is differentially altered when responding is maintained by different reinforcers and also test the pharmacologic selectively of these drug effects. Using the same monkeys, AIM 2 evaluates how chronic treatment with morphine and its discontinuation alter delay discounting under the non-drug and drug reinforced procedures; these studies examine the effects of daily treatment on delay discounting, whether tolerance develops to those effects, how discontinuation modifies delay discounting, and how the time course of changes in this measure of impulsivity correlates with indices of withdrawal. These studies examine the unexplored possibility that abuse of even small doses of opioids increases impulsivity that can be enduring; increased impulsivity might contribute to ongoing drug abuse, relapse, and other high risk behavior long after drug withdrawal is no longer evident.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Methocinnamox (MCAM): A novel opioid receptor antagonist
-
批准号:10844948
-
项目类别:
-
资助金额:$15.5万
-
财政年份:2023
-
负责人:CHARLES P FRANCE
-
依托单位:
A novel opioid receptor antagonist for treating abuse and overdose
-
批准号:10353379
-
项目类别:
-
资助金额:$49.24万
-
财政年份:2019
-
负责人:CHARLES P FRANCE
-
依托单位:
A novel opioid receptor antagonist for treating abuse and overdose
-
批准号:9892987
-
项目类别:
-
资助金额:$49.24万
-
财政年份:2019
-
负责人:CHARLES P FRANCE
-
依托单位:
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
-
批准号:10477526
-
项目类别:
-
资助金额:$14.8万
-
财政年份:2019
-
负责人:CHARLES P FRANCE
-
依托单位:
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
-
批准号:10763458
-
项目类别:
-
资助金额:$421.81万
-
财政年份:2019
-
负责人:CHARLES P FRANCE
-
依托单位:
A novel opioid receptor antagonist for treating abuse and overdose
-
批准号:10092999
-
项目类别:
-
资助金额:$49.24万
-
财政年份:2019
-
负责人:CHARLES P FRANCE
-
依托单位:
A novel opioid receptor antagonist for treating abuse and overdose
-
批准号:10561706
-
项目类别:
-
资助金额:$49.24万
-
财政年份:2019
-
负责人:CHARLES P FRANCE
-
依托单位:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
-
批准号:9008117
-
项目类别:
-
资助金额:$14.75万
-
财政年份:2013
-
负责人:CHARLES P FRANCE
-
依托单位:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
-
批准号:8714994
-
项目类别:
-
资助金额:$40.56万
-
财政年份:2013
-
负责人:CHARLES P FRANCE
-
依托单位:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
-
批准号:8652970
-
项目类别:
-
资助金额:$16.89万
-
财政年份:2013
-
负责人:CHARLES P FRANCE
-
依托单位:
Training in Drug Abuse Research: Behavior and Neurobiology
-
批准号:8266367
-
项目类别:
-
资助金额:$15.72万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Behavior, Biology, and Chemistry: Translational Research in Addiction
-
批准号:9017981
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Training in Drug Abuse Research: Behavior and Neurobiology
-
批准号:8678888
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Training in drug abuse research: behavior and neurobiology
-
批准号:9918882
-
项目类别:
-
资助金额:$42.07万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Behavior, Biology, and Chemistry: Translational Research in Addiction
-
批准号:10356925
-
项目类别:
-
资助金额:$2.75万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Postdoctoral Training in Drug Abuse Research: Behavior & Neurobiology
-
批准号:10200482
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Behavior, Biology, and Chemistry: Translational Research in Addiction
-
批准号:10573301
-
项目类别:
-
资助金额:$2.75万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Behavior, Biology, and Chemistry: Translational Research in Addiction
-
批准号:8127298
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Training in Drug Abuse Research: Behavior and Neurobiology
-
批准号:8484806
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
Behavior, Biology, and Chemistry: Translational Research in Addiction
-
批准号:8429481
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2011
-
负责人:CHARLES P FRANCE
-
依托单位:
海外基金